Evidence map›Paper›PMID 32220946›Full record

ReviewESMO open2020

Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion.

Daniele Santini, Alfredo Berruti, Massimo Di Maio, Giuseppe Procopio, Sergio Bracarda, Toni Ibrahim, Francesco Bertoldo

Erratum issuedOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ESMO open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Canadian Urological Association best practice report: Bone health in prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021
    Article
  14. Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 1 country.

Daniele SantiniDepartment of Oncology, Campus Bio-Medico University, Roma, Italy D.Santini@unicampus.it.ORCID 0000-0002-9118-3337
Alfredo BerrutiMedical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy.
Massimo Di MaioDepartment of Oncology, AO Ordine Mauriziano, Universita degli Studi di Torino, Torino, Italy.ORCID 0000-0001-8906-3785
Giuseppe ProcopioDepartment of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano, Italy.
Sergio BracardaMedical Oncology, Department of Oncology, Azienda Ospedaliera S.Maria, Terni, Italy.
Toni IbrahimOsteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Srl, Meldola, Italy.
Francesco BertoldoDepartment of Medicine, University of Verona, Verona, Italy.
A. O. Ordine Mauriziano di Torino · ITAzienda Ospedaliera S.Maria · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITUniversità Campus Bio-Medico · ITUniversity of Brescia · ITUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone health impairment is a frequent detrimental consequence of the high bone tropism of prostate cancer (PCa) cells. It is further worsened by administration of androgen-deprivation therapy (ADT), the current standard of care in the management of advanced PCa, through a rapid and dramatic increase in bone turnover and body mass changes. As a result, patients may experience substantial pain and poor quality of life (QoL) and have an increased risk of death. Notwithstanding the importance of this issue, however, bone health preservation is not yet a widespread clinical goal in daily practice.To address this urgent unmet need, following a thorough discussion of available data and sharing of their clinical practice experience, a panel of Italian experts in the field of bone health and metabolism formulated a number of practical advices for optimising the monitoring and treatment of bone health in men undergoing ADT during all phases of the disease. The rationale behind the venture was to raise awareness on the importance of bone preservation in this complex setting, while providing an instrument to support physicians and facilitate the management of bone health.Current evidence regarding the effects on bone health of ADT, of novel hormone therapies (which improve progression delay, pain control and QoL while consistently carrying the risk of non-pathological fractures in both non-metastatic and metastatic PCa) and of bone turnover inhibitors (whose use is frequently suboptimal) is reviewed. Finally, the expert opinion to optimise bone health preservation is given.

Indexed as

Bone and BonesHumansMaleProstatic Neoplasmsadvanced prostate cancerandrogen-deprivation therapybone healthmanagementnovel hormone therapy

Identifiers

PMID32220946
PMCPMC7174015
OpenAlexW3013861616

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.